摘要
目的 分析替雷利珠单抗联合卡铂与白蛋白紫杉醇在可切除头颈鳞癌新辅助治疗中的价值。方法 取2022-12月至2023-12月可切除头颈鳞癌患者50例（单臂），根据该治疗方法，结合影像学、病理学评价治疗效果。结果 治疗结果及随访结果显示：50例患者的PCR率为62.00%、PPR率为38.00%、无SD与PD病理、复发/转移率为0.00%、总生存率为100.00%、患者各不良反应发生率均不超过20.00%。结论 在可切除头颈鳞癌新辅助治疗中，替雷利珠单抗联合卡铂与白蛋白紫杉醇不仅有较好疗效，且能降低患者癌症转移或复发，提高其生存率。
关键词： 替雷利珠单抗；卡铂；白蛋白紫杉醇；可切除头颈鳞癌；新辅助治疗
Abstract
Objective To analyze the value of the combination of trastuzumab, carboplatin, and albumin paclitaxel in neoadjuvant therapy for resectable head and neck squamous cell carcinoma. Methods A total of 50 patients with resectable head and neck squamous cell carcinoma (single arm) from December 2022 to December 2023 were selected, and the treatment effect was evaluated according to this treatment method, combined with imaging and pathology. Results The results of treatment and follow-up showed that the PCR rate of 50 patients was 62.00%, the PPR rate was 38.00%, the recurrence/metastasis rate was 0.00%, the overall survival rate was 100.00%, and the incidence of adverse reactions in 50 patients was not more than 20.00%. Conclusion In neoadjuvant therapy for resectable head and neck squamous cell carcinoma, the combination of trastuzumab, carboplatin, and albumin paclitaxel not only has good therapeutic effects, but also can reduce cancer metastasis or recurrence and improve survival rates in patients.
Key words： Trelizumab; Carboplatin; Albumin paclitaxel; Resectable head and neck squamous cell carcinoma; Neoadjuvant therapy
参考文献 References
[1] 王凯,张伟,桂琳,等. 免疫联合化疗新辅助治疗在局部晚期可手术切除下咽鳞癌中的疗效及安全性[J]. 中华耳鼻咽喉头颈外科杂志,2024,59(4):343-349.
[2] 王红玲,岳恺,吴延升,等. PD-1单抗联合化疗新辅助治疗局部晚期可切除口腔鳞癌的Ⅱ期临床研究[J]. 中华耳鼻咽喉头颈外科杂志,2024,59(4):335-342.
[3] 付海琴,南阳光,李春燕,等. 白蛋白紫杉醇与卡铂联合替雷利珠单抗治疗晚期非小细胞肺癌的效果[J]. 西北药学杂志,2023,38(4):164-168.
[4] 濮荔. 白蛋白紫杉醇、卡铂联合替雷利珠单抗用于非小细胞肺癌的疗效及对患者T淋巴细胞水平的影响[J]. 大医生,2024,9(22):62-65.
[5] 王鹏,郝朋朋,李全奎. 一线PD-1单抗与贝伐单抗双靶联合化疗治疗晚期非鳞非小细胞肺癌临床观察[J]. 社区医学杂志,2023,21(20):1052-1057.
[6] 汪李琴,陈海兵,龚霄阳,等. 新辅助抗PD-1/PD-L1在可手术切除的头颈部鳞状细胞癌中的疗效及安全性分析与评价[J]. 中国耳鼻咽喉颅底外科杂志,2024,30(3):23-33.
[7] 吴琴,吴栋,谢健龙,等. 替雷利珠单抗联合化疗在可切除食管癌新辅助治疗中的疗效及安全性评价[J]. 国际肿瘤学杂志,2024,51(10):620-626.
[8] 宋攀,梁发雅,叶煜初,等. 替雷利珠单抗单药治疗复发或转移性头颈部鳞状细胞癌[J]. 临床耳鼻咽喉头颈外科杂志,2023,37(10):778-785.